Medicine

Metronodazole

Indications: This medicine is an anti-infective used to treat infections primary caused by Amoebae, Trichomonas and Giardia.

Directions for use: Depends of indication 200 ?800 mg three times the day

Pregnancy: May not be used

Side effects: include stomach upset, loss of appetite, constipation, headache, or metallic taste. If they continue or are bothersome, check with your doctor. CHECK WITH YOUR DOCTOR AS SOON AS POSSIBLE if you experience rash; vomiting; sore throat or fever; numbness, tingling, or burning of your arms, hands, legs, or feet; or seizures. If you notice any other effects not listed above, contact your doctor, nurse, or pharmacist.

Metronidazol Resource:

Why do metabolites circulate?
Smith DA, Dalvie D.
Xenobiotica. 2012 Jan;42(1):107-26. Epub 2011 Nov 24. Review
Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner.
Semighini CP, Averette AF, Perfect JR, Heitman J.
PLoS Pathog. 2011 Nov;7(11):e1002364. Epub 2011 Nov 17
The Cu(II)-fluconazole complex revisited. Part I: Structural characteristics of the system.
Nagaj J, Starosta R, Szczepanik W, Barys M, Młynarz P, Jeżowska-Bojczuk M.
J Inorg Biochem. 2012 Jan;106(1):23-31. Epub 2011 Sep 25
Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T, Laitila J, Niemi M, Neuvonen PJ, Backman JT.
Eur J Clin Pharmacol. 2012 May;68(5):681-8. Epub 2011 Nov 23
Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.
Zhang S, Pillai VC, Mada SR, Strom S, Venkataramanan R.
Xenobiotica. 2012 May;42(5):409-16. Epub 2011 Nov 22
Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm.
Yu LH, Wei X, Ma M, Chen XJ, Xu SB.
Antimicrob Agents Chemother. 2012 Feb;56(2):770-5. Epub 2011 Nov 21
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area.
D'Avino A, Di Giambenedetto S, Fabbiani M, Farina S.
Diagn Microbiol Infect Dis. 2012 Feb;72(2):185-7. Epub 2011 Nov 21
Internal transcribed spacer region sequence analysis using SmartGene IDNS software for the identification of unusual clinical yeast isolates.
Slechta ES, Hohmann SL, Simmon K, Hanson KE.
Med Mycol. 2011 Nov 22. [Epub ahead of print
Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data.
Dvorak CC, Fisher BT, Sung L, Steinbach WJ, Nieder M, Alexander S, Zaoutis TE.
Pediatr Blood Cancer. 2012 Jul 15;59(1):21-6. doi: 10.1002/pbc.23415. Epub 2011 Nov 18
Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units.
Tortorano AM, Prigitano A, Dho G, Grancini A, Passera M; ECMM-FIMUA Study Group.
J Med Microbiol. 2012 Mar;61(Pt 3):389-93. Epub 2011 Nov 17
Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients.
Anekthananon T, Manosuthi W, Chetchotisakd P, Kiertiburanakul S, Supparatpinyo K, Ratanasuwan W, Pappas PG, Filler SG, Kopetskie HA, Nolen TL, Kendrick AS, Larsen RA; BAMSG 3-01 Study Team.
Int J STD AIDS. 2011 Nov;22(11):665-70
Molecular analysis and dimorphism of azole-susceptible and resistant Candida albicans isolates.
Costa CR, Hasimoto e Souza LK, Ataídes FS, Ferri PH, da Costa MP, Fernanades Ode F, Silva Mdo R.
Rev Soc Bras Med Trop. 2011 Nov-Dec;44(6):740-4. Epub 2011 Nov 21
Functional characterization of the regulators of calcineurin in Candida glabrata.
Miyazaki T, Izumikawa K, Nagayoshi Y, Saijo T, Yamauchi S, Morinaga Y, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Miyazaki Y, Kohno S.
FEMS Yeast Res. 2011 Dec;11(8):621-30. doi: 10.1111/j.1567-1364.2011.00751.x. Epub 2011 Sep 19
[In vitro biofilm formation and relationship with antifungal resistance of Candida spp. isolated from vaginal and intrauterine device string samples of women with vaginal complaints].
Calışkan S, Keçeli Özcan S, Cınar S, Corakçı A, Calışkan E.
Mikrobiyol Bul. 2011 Oct;45(4):697-706. Turkish.
Iliopsoas abscess caused by Aspergillus fumigatus complicated by pulmonary aspergillosis.
Yoshida K, Shoji H, Takuma T, Eguchi J, Imawari M, Niki Y.
J Infect Chemother. 2011 Nov 15. [Epub ahead of print
Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis.
Muzoora CK, Kabanda T, Ortu G, Ssentamu J, Hearn P, Mwesigye J, Longley N, Jarvis JN, Jaffar S, Harrison TS.
J Infect. 2012 Jan;64(1):76-81. Epub 2011 Nov 4
Synthesis and antifungal activity of novel triazole derivatives.
Yan Y, Yu S, Chai X, Hu H, Wu Q.
Arch Pharm Res. 2011 Oct;34(10):1649-56. Epub 2011 Nov 12
Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains.
Vitale RG, Pascuccelli V, Afeltra J.
J Med Microbiol. 2012 Mar;61(Pt 3):384-8. Epub 2011 Nov 10
Voriconazole, Combined with Amphotericin B, in the Treatment for Pulmonary Cryptococcosis Caused by C. neoformans (Serotype A) in Mice with Severe Combined Immunodeficiency (SCID).
Silva EG, Paula CR, de Assis Baroni F, Gambale W.
Mycopathologia. 2012 Jun;173(5-6):445-9. Epub 2011 Nov 10
Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents.
Ahsan MJ, Samy JG, Khalilullah H, Nomani MS, Saraswat P, Gaur R, Singh A.
Bioorg Med Chem Lett. 2011 Dec 15;21(24):7246-50. Epub 2011 Oct 20
First Prev 8 9 10 11 12 13 14 15 16 Next Last 432/8628 Jump: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432

Back to list of medicine • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment. All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.